104 related articles for article (PubMed ID: 6205938)
1. [Basis for the potential production of immune preparations against Pseudomonas aeruginosa from the blood of convalescent burn patients].
Povstianoĭ NE; Kolker II; Nazarchuk LV; Fedorovskaia EA; Litovchenko PP
Gematol Transfuziol; 1984 Jul; 29(7):56-8. PubMed ID: 6205938
[No Abstract] [Full Text] [Related]
2. [Donor plasma with anti-Pseudomonas aeruginosa activity as a directed-action preparation].
Nazarchuk LV
Vrach Delo; 1987 Jul; (7):96-8. PubMed ID: 3114958
[No Abstract] [Full Text] [Related]
3. [Polish preparations for preventing and treating infections caused by Pseudomonas aeruginosa].
Schiller B; Buchowicz I; Lysakowska E; Sakiel S; Korbecki M
Zh Mikrobiol Epidemiol Immunobiol; 1985 Apr; (4):30-2. PubMed ID: 2409720
[TBL] [Abstract][Full Text] [Related]
4. [Results of using polyvalent Pseudomonas aeruginosa vaccine in children with burns by various medical centers].
Bbukowska D; Serafińska D; Rudowski W; Hoffman S; Olański W; Gardzińska E; Popiel D; Jedrzejczak G; Czarnecka I
Pol Tyg Lek; 1989 Oct 23-Nov 6; 44(43-45):924-7. PubMed ID: 2518666
[TBL] [Abstract][Full Text] [Related]
5. [Antigenic properties of Pseudomonas aeruginosa anatoxin and the protective action of antitoxic anti-Pseudomonas aeruginosa serum].
Podgornaia LG; Dziuban NF
Zh Mikrobiol Epidemiol Immunobiol; 1986 Jun; (6):67-9. PubMed ID: 3092510
[TBL] [Abstract][Full Text] [Related]
6. Anti-PcrV IgY antibodies protect against Pseudomonas aeruginosa infection in both acute pneumonia and burn wound models.
Ranjbar M; Behrouz B; Norouzi F; Mousavi Gargari SL
Mol Immunol; 2019 Dec; 116():98-105. PubMed ID: 31634816
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the immune responses following co-administration of PilQ and type b-flagellin from Pseudomonas aeruginosa in the burn mouse model.
Bakht Azad S; Nikokar I; Faezi S; Rasooly S; Mahdavi M
Microb Pathog; 2018 Oct; 123():426-432. PubMed ID: 30075242
[TBL] [Abstract][Full Text] [Related]
8. [Sensitization to Pseudomonas aeruginosa in thermal burn patients].
Kolker II; Minkina AE; Fradkin VA; Panova IuM; Morozov SS
Klin Med (Mosk); 1982 Jun; 60(6):103-7. PubMed ID: 6811796
[No Abstract] [Full Text] [Related]
9. Thermal injury-induced non-specific resistance to fatal Pseudomonas aeruginosa burn-infection in mice.
Pinto M; Zehavi-Willner T
Jpn J Exp Med; 1989 Oct; 59(5):189-96. PubMed ID: 2559218
[TBL] [Abstract][Full Text] [Related]
10. PcrV immunization enhances survival of burned Pseudomonas aeruginosa-infected mice.
Holder IA; Neely AN; Frank DW
Infect Immun; 2001 Sep; 69(9):5908-10. PubMed ID: 11500471
[TBL] [Abstract][Full Text] [Related]
11. Antibody response to outer-membrane antigens of Pseudomonas aeruginosa in human burn wound infection.
Ward KH; Anwar H; Brown RW; Wale J; Gowar J
J Med Microbiol; 1988 Nov; 27(3):179-90. PubMed ID: 3143013
[TBL] [Abstract][Full Text] [Related]
12. Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa: immunization using divalent flagella preparations.
Holder IA; Naglich JG
J Trauma; 1986 Feb; 26(2):118-22. PubMed ID: 2418208
[TBL] [Abstract][Full Text] [Related]
13. Flagellin and pilin immunization against multi-drug resistant Pseudomonas aeruginosa protects mice in the burn wound sepsis model.
Korpi F; Hashemi FB; Irajian G; Fatemi MJ; Laghaei P; Behrouz B
Immunol Lett; 2016 Aug; 176():8-17. PubMed ID: 27210422
[TBL] [Abstract][Full Text] [Related]
14. Immunization of burn-patients with a Pseudomonas aeruginosa outer membrane protein vaccine elicits antibodies with protective efficacy.
Lee NG; Jung SB; Ahn BY; Kim YH; Kim JJ; Kim DK; Kim IS; Yoon SM; Nam SW; Kim HS; Park WJ
Vaccine; 2000 Mar; 18(18):1952-61. PubMed ID: 10699346
[TBL] [Abstract][Full Text] [Related]
15. [The changes of the OEP-HA titer in the sera of mice challenged with Pseudomonas aeruginosa and in the phagocytic system of macrophages in vitro (author's transl)].
Satomi N; Haranaka K; Kunii O; Mashimo K
Kansenshogaku Zasshi; 1979 Aug; 53(8):350-8. PubMed ID: 119815
[No Abstract] [Full Text] [Related]
16. Effects of somatic component of Pseudomonas aeruginosa on protective immunity in experimental mouse burn infection.
Okada K; Kawaharajo K; Kasai T; Homma JY
Jpn J Exp Med; 1980 Feb; 50(1):53-61. PubMed ID: 6770131
[TBL] [Abstract][Full Text] [Related]
17. [Safety, reactogenicity and efficacy of pyoimmunogen in immunizing burn patients].
Grishina IA; Panova IuM; Kolker II; Stanislavskii ES; Zarubina EK
Zh Mikrobiol Epidemiol Immunobiol; 1982 Jul; (7):34-7. PubMed ID: 6812327
[TBL] [Abstract][Full Text] [Related]
18. Bivalent flagellin immunotherapy protects mice against Pseudomonas aeruginosa infections in both acute pneumonia and burn wound models.
Ahmadi H; Behrouz B; Irajian G; Amirmozafari N; Naghavi S
Biologicals; 2017 Mar; 46():29-37. PubMed ID: 28065582
[TBL] [Abstract][Full Text] [Related]
19. [Dynamics of humoral antibody formation against the O-antigen of Pseudomonas aeruginosa in suppurative diseases].
Zarubina EK; Svetukhin AM; Edvabnaia LS
Khirurgiia (Mosk); 1980 Nov; (11):47-52. PubMed ID: 6777579
[No Abstract] [Full Text] [Related]
20. Opsonic and protective activity of five human IgM monoclonal antibodies reactive with lipopolysaccharide antigen of Pseudomonas aeruginosa.
Collins MS; Ladehoff DK; Mehton NS; Noonan JS
FEMS Microbiol Immunol; 1990 Dec; 2(5-6):263-8. PubMed ID: 2127368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
